Second, we have seen continued growth of ADCETRIS in Stage III and IV frontline Hodgkin lymphoma. This reflects a positive reception to the three-year PFS data from Echelon-1 trial reported at ASCO. In addition, there has been an increase in patient engagement with growth in unique visitors to our online resources and downloads of the ask your doctor brochures. This encourages patients to ask their physicians about all available options for frontline treatment of Hodgkin lymphoma.